Navigation Links
New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
Date:8/27/2007

stage medicinal chemistry. The scarcity of intellectual and financial capital for this essential part of the drug discovery process between the lab bench and the clinical drug development process is Australia's great funding gap.

"CTx will provide an integrated and coherent pathway for drug discovery, commercialisation and clinical development. Currently, the standard model of drug development can present a frustrating conundrum for medical researchers. The discovery of a new compound, which may well possess the qualities to be transformed into a new drug, requires further substantial investment to properly demonstrate its potential. At this point, research organisations operating on tight budgets and with limited development experience and/or capabilities feel that further investment is beyond their grasp. In addition, pharmaceutical companies are reluctant to take on the development of compounds at a very early stage because their likelihood of success has not been established. Consequently, a promising compound often fails to reach even the early clinical testing phase."

Dr Ian Street, Chief Scientific Officer of CTx, adds, "That's where CTx comes in. We have a unique combination of skills, ranging from independent, expert scientific assessment and validation through to drug development, commercialisation and clinical application. CTx is now establishing its drug discovery operations in key locations throughout Australia and has already identified a number of exciting projects to initiate its development programs."

For more information

Cancer Therapeutics CRC Pty Ltd CEO

Dr Julian Clark Tel: +61-3-9345-2612

e-mail: jclark@wehi.edu.au

Notes to editors:

CTx has created a world-class translational research organisation headquartered at The Walter and Eliza Hall Institute's Biotechnology Centre at Bundoora, in north-eastern Melbourne, Victoria and brings together Australia's fo
'/>"/>

SOURCE Cancer Therapeutics CRC Pty Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
4. FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc.
5. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
6. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
11. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... MicroDose Technologies,Inc. (MicroDose) today announced that the first ... Inc., through a Merck affiliate, has been,achieved, triggering ... MicroDose,s dry powder inhaler (DPI) technology announced in ... of a Phase I clinical,study of an investigational ...
... -Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular ... ... SUNNYVALE, Calif., Aug. 5 Icon Bioscience, Inc., (IBI),a privately ... its Phase I clinical trial to assess the,safety and efficacy of ...
Cached Medicine Technology:MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc. 2Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate 2
(Date:4/24/2014)... 28, the Center for BrainHealth will bring together ... pressing brain-related challenges at its inaugural Brain Health ... Regeneration." Featured speakers will include Dr. Sandra Bond ... for BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. ... Assistant Secretary for Policy and Early Learning, U.S. ...
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
(Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... the worldwide leader of post-breast surgery products, ... Collection, the industry,s first post-surgical garments infused ... discomfort after breast surgery.(Logo: ... http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 )The post-surgical camisole and ...
... NORTH BRUNSWICK┬┐ N.J.┬┐ April 8 ORTHOCON┬┐ Inc. today ... company as President and Chief Executive Officer. The company ... of financing led by top-tier healthcare investors. ORTHOCON ... bone. The Company,s versatile technology platform may be leveraged ...
... for good nutrition but lack knowledge of food prep ... the current economic conditions, three-quarters of what people eat ... dependent on what food families keep in their kitchens. ... freezers, Rutgers University researchers found that, in ...
... Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today ... (BGM) in its Phase 2 clinical safety trial with ... BGM will measure levels of Galectin-3 in patients enrolled ... remodeling associated with advanced stages of heart failure. CDP-1050 ...
... NORTHFIELD, Ill., April 8 The College of American ... accreditation organization and deeming authority under the Clinical Laboratory ... and Medicaid Services (CMS) since 1995, has been notified ... subspecialties for a six-year period, the longest period available ...
... LAS VEGAS, April 8 Scheduled for June 5 ... garnered broad industry support and surpassed previous levels of ... this annual medical education and commercial exhibition event has ... a focal point for the high-growth medical aesthetic industry. ...
Cached Medicine News:Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 2Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 4Health News:CAP Deeming Status Renewed 2Health News:THE Aesthetic Show Attracts Record Sponsorship 2Health News:THE Aesthetic Show Attracts Record Sponsorship 3
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: